Recent Company News

• 02:40 PM ET Jun 12, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 14-June

• 04:45 PM ET Jun 09, 2026
  

  Transcript Intelligence: argenx at Goldman Sachs Global Healthcare Conference ($884.00, +1.59)

• 01:55 PM ET Jun 05, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 7-June

• 02:25 PM ET Jun 03, 2026
  

  Transcript Intelligence : argenx à la William Blair Growth Stock Conference ($812.38, +10.21)

• 02:25 PM ET Jun 03, 2026
  

  Transcript Intelligence: argenx at William Blair Growth Stock Conference ($812.38, +10.21)

• 01:05 AM ET Jun 03, 2026
  

  argenx presents new data on VYVGART at EULAR 2026 ($802.17, 0.00)

• 02:23 PM ET May 12, 2026
  

  Transcript Intelligence: argenx at Bank of America Securities Healthcare Conference ($817.50, +4.22)

• 05:31 PM ET May 11, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:49 AM ET May 11, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:27 PM ET May 08, 2026
  

  argenx announces US FDA approval expanding VYVGART and VYVGART Hytrulo for use in all adult patients living with generalized myasthenia gravis ($782.17, 0.00)